Efficacy and safety of Tetramethylpyrazine (TMP) Phosphate on Pulmonary Hypertension: study protocol for a randomized controlled trial

CURRENT STATUS: ACCEPTED

Jian Wang
State Key Laboratory of respiratory disease
Corresponding Author
ORCiD: 0000-0002-1278-256X

Yuqin Chen
Skate Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Wenjun He
National Institute of Tuberculosis and Respiratory Diseases

Haiping Ouyang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Chunli Liu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Cheng Hong
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Tao Wang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Kai Yang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Wenju Lu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

DOI:
10.21203/rs.2.9435/v1

SUBJECT AREAS
Interdisciplinary Medicine

KEYWORDS
pulmonary hypertension, tetramethylpyrazine, randomized controlled study
Abstract

**Background:** Tetramethylpyrazine (TMP), an active ingredient in the traditional Chinese herbal medicine Rhizoma Chuanxiong, has been used clinically for the prevention and treatment of cardiovascular disease. The benefits of TMP are largely attributed to its antioxidative and vasodilative properties. However, the efficacy of TMP in the treatment of pulmonary hypertension (PH) is unknown. We hypothesized that TMP may have a therapeutic effect in patients with PH.

**Methods:**

A randomized, single-blinded, clinical study with a TMP treatment group and a control group will be conducted to evaluate the efficacy and safety of TMP intervention in patients with PH. The recruitment target is 120 subjects meeting the following criteria: (i) At rest and at sea level, mean pulmonary artery pressure above 20 mmHg and pulmonary capillary wedge pressure below 15 mmHg; (ii) Type 1 or 4 PH in the stable phase; (iii) age 15–70 years; (iv) 6-minute walk distance between 100 and 450 meters; (v) lung function at level II, III, or IV according to WHO classification. Subjects will be assigned randomly into two groups at a ratio of 1:2 (control:TMP). Both groups will receive routine treatment, and the treatment group will also receive oral TMP (100 mg) three times a day for 16 weeks. All patients will be followed up for 4, 8, 12, and 16 weeks, and symptoms and patient compliance will be recorded.

**Discussion:**

We aim to determine the efficacy and safety of TMP for the treatment of PH.

**Study registration:**

ChiCTR1800018664, http://www.chictr.org.cn/edit.aspx?pid=31565&htm=4 (registered on 2 October 2018).
Background

Pulmonary hypertension (PH) is a serious condition characterized by sustained elevated mean pulmonary arterial pressure (mPAP) over 20 mmHg and the development of right heart hypertrophy, leading to cardiac failure and, ultimately, death. [1-4]. With improvements in diagnostic techniques, PH is no longer a rare disease. According to the latest epidemiological data, the prevalence of PH is about 1% of the global population.[5] Although understanding of the pathophysiology and pathogenesis of PH has increased, and quality of life of patients has improved significantly through the use of targeted drugs, persistent high mortality rates indicate that these drugs delay the progression of the disease and alleviate symptoms but do not effectively prolong the life of the patients.[6-9] In addition, the use of effective drugs is limited by their high cost. Therefore, it is imperative to develop new and affordable medications with strong efficacy and safety profiles.

Given its anti-oxidative, anti-myocardial injury, and vasodilative effects [10-13], tetramethylpyrazine (TMP), a traditional Chinese herbal medicine, is widely used in the treatment of cardiovascular and cerebrovascular diseases [14-17]. The pathogenesis of PH involves oxidative stress, vascular inflammation, and imbalance of intracellular calcium homeostasis [18-20]. However, it has not yet been reported whether TMP has a therapeutic effect on PH. In our previous study, we showed that TMP intervention improves calcium imbalance in pulmonary artery smooth muscle cells (PASMCs) by modulating the expression of TRPC1, TRPC6, Kv1.5, and Kv2.1 in a rat model of PH, potentially reducing intracellular free calcium concentration ([Ca $^2+$]i) to reduce the contraction and proliferation of PASMCs and improving pulmonary distal arteriolar remodeling. Regulation of [Ca$^{2+}$]i in PASMCs may therefore represent a target for the treatment of PH, providing a basis for the development of new therapies for this condition.
We therefore designed a 16-week randomized, double-blinded, clinically controlled study to examine the efficacy and safety of TMP phosphate for the treatment of PH.

Methods

Study design

We designed a study protocol for a randomized controlled study. Screening (Visit 0) was undertaken within 3 days prior to enrollment to assess eligibility and collect baseline data. Subjects who entered the primary screening were assessed for lung function, and those meeting all criteria were randomly assigned (2:1) into a TMP treatment group or a control group. Both groups received conventional treatment, and the TMP treatment group also received 100 mg oral TMP three times daily. Patients were followed up at 1 month after randomization (Visit 1), and then every month until end of treatment at 16 weeks. Data collected at Visit 0 included patient characteristics (name, sex, age), medical history, concomitant medications, laboratory and auxiliary examinations, and adverse events. Additionally, at each visit, medical history, medications, cardiac and pulmonary function, and adverse events will be collected. Additional items will be evaluated at Visits 2 and 4. A schedule of assessments is shown in Table 1. A study flow chart is shown in Figure 1.

Sampling

Based on the 6-minute walk distance (6MWD) as the main efficacy index, it is assumed that after treatment, the experimental group has an average distance of 60 m from the control group of 6 minutes, the standard deviation is 60 m, α is 0.05, and the efficacy is 90% (β is 0.10). The sample size is:

See supplemental files for the formula
q1 is the proportion of the experimental group, and q2 is the proportion of the control group, q1 = 2/3, q2 = 1/3, N ≈ 107.

Assume that the sample shedding rate is 11%, the sample size is approximately 120 participants, comprising 40 patients with control, 80 patients in TMP group.

Study procedure

Eligibility criteria for enrollment

The selection of participants will be based on the following inclusion and exclusion criteria:

Inclusion criteria

1. In accordance with the diagnostic criteria for PH, mPAP measured by right cardiac catheterization above 20 mmHg and pulmonary capillary wedge pressure (PCWP) below 15 mmHg, at sea level and in a resting state.

2. Subjects with Type 1 or Type 4 PH classified according to the World Symposium on Pulmonary Hypertension (2015 ESC/ERS guideline.) [21] who are in a stable stage, including idiopathic PH, hereditary PH, PH induced by drugs or toxins, PH associated with connective tissue diseases or congenital heart diseases (with no surgery/intervention within the previous 6 months); and chronic thromboembolic PH (surgical treatment is preferred for patients with surgical indications. For patients who have PH after surgery, are without surgical indications, or are nonoperable ones, stabilization with anticoagulant drugs (such as warfarin) for at least 1 month prior to participation is required).
3. Age 15–70 years, male or female.

4. WHO PH functional classification II, IV, or V.

5. 6MWD of >100 m and <450 m at baseline.

6. Patients stable for at least 1 month after standard treatment, and patients who have not received treatment with interventional or surgical closure in the 6 months prior to participation.

7. Patient or his/her guardian agrees to participation of the patient in the study and provides written informed consent for participation.

Exclusion criteria

1. Absent or limited legal capacity.

2. Pregnant or lactating women.

3. Serious primary diseases in major organs.

4. Mental or physical disability preventing the completion of 6MWD.

5. Suspected or confirmed history of alcohol or substance abuse.

6. Known allergy to the components of the drug.

7. AST and ALT values above 3 times the upper limit of normal, or Ccr <50 ml/min.
8. Low systemic blood pressure (<90/50 mmHg) or uncontrolled hypertension (blood pressure >170/110 mmHg).

9. Prior use of the study drug and discontinuation or change in targeted drugs (e.g. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate cyclase) in the 3 months prior to screening.

10. Presence of an active infectious disease such as hepatitis A, hepatitis B, AIDS, tuberculosis, or connective tissue diseases.

11. Presence of serious infection, especially pulmonary infections.

12. Shock or other hemodynamically unstable conditions.

13. Cirrhosis or portal hypertension caused by cirrhosis.

14. Severe bleeding or bleeding tendency such as active peptic ulcer, intracranial hemorrhage, trauma, or other bleeding events.

15. Acute or chronic organic diseases (except for dyspnea) or other conditions (such as limb diseases) which may result in the subject being unable to complete the study (especially the 6MWD).

16. Any other circumstances under which the investigator considers the patient to be unsuitable for participation in the study.

Withdrawal criteria
1. Subjects having poor compliance with the dosing regimen

2. Use or accidental use of foods or drugs that may impact test results during the treatment period (e.g., amirace, fenfluramine, dexfenfluramine, L-tryptophan, methamphetamine, and phenylflurazone)

3. Subjects with incomplete key data that may affect the statistical analysis.

Endpoint standards

1. Subjects experiencing serious adverse reactions leading to suspension or termination of treatment during the study

2. Subjects whose condition deteriorates during the study

3. Subjects who withdraw consent or are unable to complete the study because of other circumstances

4. Patients treated with targeted drugs for Type 1 or Type 4 PH prior to testing who stopped treatment with the targeted drug for any reason during the study and did not reinitiate treatment

5. Death (from PH or another cause).

Drugs and usage

Subjects satisfying all criteria are assigned (2:1) randomly into two groups as follows:
1. TMP treatment group: TMP 100 mg 3 times daily in addition to routine therapy.

2. Control group: routine therapy only.

TMP was produced by Livzon Pharmaceutical Group Inc. (Zhuhai, Guangdong Province, China), following the instructions of the People’s Republic of China Pharmacopoeia [22]. Routine therapy does not differ between two groups, and included phosphodiesterase type 5 inhibitors (sildenafil and tadalafil). Where subjects have previously received targeted drugs for the treatment of PH, the regimen will remain unchanged.

Outcome measurements

Efficacy indicators

The main efficacy indicators are the 6MWD and heart rate recovery at 1 minute (HRR1) after the 6MWD (Table 2).

Secondary efficacy measurements include the following 12 indicators (Table 2): PH WHO Classification, Borg Dyspnea Score, Minnesota Living with Heart Failure Questionnaire (MLHFAQ), NT-proBNP (N-terminal pro-brain natriuretic peptide), cTNI (cardiac troponin I), right ventricular systolic pressure (RVSP) evaluated by echocardiogram, uric acid, volume of pericardial effusion, pulmonary artery diameter assessed by CT, diameter of the same layer of aorta assessed by CT, arterial oxygen saturation, and time of clinical deterioration.

Safety evaluation
Symptoms and signs including respiration rate, heart rate, and blood pressure are recorded at each visit. Laboratory tests are performed within 3 days prior to enrollment, and include routine blood tests and urinalysis, liver function, renal function, coagulation function, and electrocardiography. Adverse events are assessed and then recorded in the CRF.

Evaluation of adverse events

Adverse events, including symptoms, signs, and physical or laboratory examination abnormalities, are carefully evaluated. All adverse events must be judged for their character, severity, and potential relationship to the study treatment. The correlation between adverse events and study treatment is divided into five levels: definite, probable, possible, unrelated.

Data management and statistical analyses

Data from each subject visit will be captured in the CRF.

Statistical analysis of the efficacy of the study will be performed using statistical data sets that met the protocol. The data will be analyzed by two-sided test t test, with categorical variables analyzed by χ2 test and rank variables by paired Wilcoxon rank sum test. The test level α is 0.05, and the P values ≤0.05 will be considered statistically significant.

Ethics

The present study is being conducted in accordance with the Declaration of Helsinki and
relevant clinical study research regulations in China. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University. Prior to participation, all subjects must provide written informed consent.

Discussion

There is little evidence to date of the efficacy and safety of TMP therapy for PH. Targeted drugs with limited efficacy are expensive. The present clinical study is expected to provide evidence for the safety and efficacy of TMP, a new affordable potential treatment for PH.

Then plan to subsequently conduct a large-scale clinical study to comprehensively evaluate the efficacy and safety of TMP in the treatment of PH, based on the findings of the present study.

Study Status

Recruitment started in September 2018 and is planned to end in October 2018, with 120 patients randomized. Treatment with TMP is ongoing at present and expected to finish in October 2019. The current protocol version is 2.0, dated 28 September 2018.

List Of Abbreviations

6MWD: 6-minute walk distance, CRF: case report form, cTNI: cardiac troponin I, HRR1: heart rate recovery at 1 minute, Minnesota Living with Heart Failure Questionnaire: MLHFQ, NT-proBNP: N-terminal pro-brain natriuretic peptide, RVSP: right ventricular systolic pressure, WHO: World Health Organization, PH: pulmonary hypertension, TMP: tetramethylpyrazine.

Declarations
Ethics approval and consent to participate

This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University. Prior to participation, all subjects must provide written informed consent.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported in part by the grants from the National Natural Science Foundation of China (81630001), Department of Science and Technology of China grants (2016YFC1304102, 2016YFC0903700), Changjiang Scholars and Innovative Research Team in University grant IRT0961, Guangdong Department of Science and Technology grants (2017A020215114, 2016A030311020, 2016A030313606), Guangzhou Department of Education Yangcheng Scholarship (12A001S), Guangzhou Department of Education Scholarship (1201630095), State Key Laboratory of Respiratory Disease grant (SKLRD-QN-201704), Guangzhou Department of Science and Technology (2014Y2-00167) and the Guangdong Province Universities, Colleges Pearl River Scholar Funded Scheme of China.
Authors’ contributions

JW is the coordinator of the study, WH wrote the first draft of the manuscript. YC was critically involved as co-principal investigator in the planning and the conduct of the study (application for funding and trial design) and in finalizing the manuscript. HOY and KY were involved in critically revising the manuscript. TW helped to finalize the manuscript. CH and CL were investigators at the clinical site. WL was responsible for planning all statistical analyses. All authors read and approved the final manuscript.

Acknowledgements

We thank Clare Cox, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Author Details

Not applicable.

References

1. Lo CCW, Moosavi SM, Bubb KJ: The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. Front Physiol 2018, 9:1167.

2. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O: Pulmonary Arterial Hypertension: New Pathophysiological Insights and Emerging Therapeutic Targets. Int J Biochem Cell Biol 2018.

3. Meyer G: Effective diagnosis and treatment of pulmonary embolism: Improving patient
outcomes. *Arch Cardiovasc Dis* 2014, 107:406-414.

4. Valverde AB, Soares JM, Viana KP, Gomes B, Soares C, Souza RPulmonary arterial hypertension in Latin America: epidemiological data from local studies *BMC Pulm Med* 2018, 18:106.

5. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC, Gibbs JS: A global view of pulmonary hypertension. *Lancet Respir Med* 2016, 4:306-322.

6. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra AM, et al: Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. *Int J Cardiol* 2018.

7. Berthelot E, Bauer F, Eicher JC, Flecher E, Gellen B, Guihaire J, Guijarro D, Roul G, Salvat M, Tribouilloy C, et al: Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. *ESC Heart Fail* 2018.

8. Petry A, Trautz B, Kracun D, Zhang Z, Vogel F, Weitnauer M, Hochkogler K, Gorlach A: Stabilization of p22phox by hypoxia promotes pulmonary hypertension. *Antioxid Redox Signal* 2018.

9. Huber LC, Leuenberger C, Kohler M, Brock M: Pulmonary hypertension: microRNAs in pathogenesis, diagnosis and therapy. *Pneumologie* 2014, 68:386-393.

10. Chen HP, He M, Huang QR, Zeng GH, Liu D Delayed protection of tetramethylpyrazine on neonatal rat cardiomyocytes subjected to anoxia-reoxygenation injury. *Basic Clin Pharmacol Toxicol* 2007, 100:366-371.
11. Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Zhang J, Wang S: Tetramethylpyrazine (TMP) exerts antitumor effects by inducing apoptosis and autophagy in hepatocellular carcinoma. *Int Immunopharmacol* 2015, 26:212-220.

12. Liu X, Liu H, Zeng Z, Zhou W, Liu J, He Z: Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect. *Int J Nanomedicine* 2011, 6:1391-1398.

13. Tsai CC, Lai TY, Huang WC, Liu IM, Liou SS: Role of cGMP signals in tetramethylpyrazine induced relaxation of the isolated rat aortic strip. *Life Sci* 2005, 77:1416-1424.

14. Sun MY, Zhang M, Chen SL, Zhang SP, Guo CY, Wang JS, Liu X, Miao Y, Yin H: The Influence of Hyperlipidemia on Endothelial Function of FPN1 Tek-Cre Mice and the Intervention Effect of Tetramethylpyrazine. *Cell Physiol Biochem* 2018, 47:119-128.

15. Guo M, Liu Y, Shi D: Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms. *Biomed Res Int* 2016, 2016:2430329.

16. Zhao Y, Liu Y, Chen K: Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective. *Oxid Med Cell Longev* 2016, 2016:2124638.

17. Li H, Yang X, Shi W, Ma Z, Feng GK, Yin YL, Fan YX, Jiang P: Protective Effects of Tetramethylpyrazine on Cerebrovascular Regulations in Rats with Chronic Alcoholic Encephalopathy. *Biomed Environ Sci* 2015, 28:691-695.
18. Mirrakhimov AE, Strohl KP: High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management. *Open Cardiovasc Med J* 2016, 10:19-27.

19. Huber LC, Bye H, Brock M: The pathogenesis of pulmonary hypertension--an update. *Swiss Med Wkly* 2015, 145:w14202.

20. Qian W, Xiong X, Fang Z, Lu H, Wang Z: Protective effect of tetramethylpyrazine on myocardial ischemia-reperfusion injury. *Evid Based Complement Alternat Med* 2014, 2014:107501.

21. Galiè N, Humbert M, Vachiery JL, Gibbs S: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) *Eur Heart J* 2016, Jan 1;37(1):67-119.

22. People’s Republic of China Pharmacopoeia. http://www.livzon-nnr.com/.

Tables

Table 1 Study schedule of assessments

| Visit cycle evaluation projects | Screening stage | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
|---------------------------------|----------------|--------|--------|--------|--------|
| Time-Window                     | Day -3-0       | Week 4 | Week 8 | Week 12| Week 16|
| Inclusion and exclusion criteria| √              |        |        |        |        |
| Test                                      | √, required |
|-------------------------------------------|-------------|
| Informed consent                          | √           |
| Basic condition                           | √           |
| Basic medical history                     | √           |
| Complication                              | √, √, √, √, √, √ |
| Symptoms and signs                        | √, √, √, √, √ |
| Drug combination                          | √, √, √, √, √ |
| Blood routine test, urine routine, liver and kidney function, coagulation function | √, √ |
| Evaluation of cardiopulmonary function (6MWD, WHO-FC, Borg Score, MLHFQ) | √, √, √, √ |
| Electrocardiogram                         | √, √, √, √, √ |
| Imaging                                   | √, √, √, √, √ |
| Arterial blood gases                      | √, √, √, √, √ |
| NT-proBNP, cTNI levels                    | √, √, √, √, √ |
| Echocardiography                          | √, √, √, √, √ |
| Pulmonary function test                   | √, √, √, √, √ |
| Adverse events                            | √, √, √, √, √ |

Basic medical history contains current medical history (symptoms and signs) and previous history.

Evaluation of cardiac and pulmonary function includes a 6-minute walk distance (6MWD),
Minnesota Living with Heart Failure Questionnaire (MLHFQ), Borg Score, and World Health Organization functional class (WHO-FC)

Safety parameters include routine blood tests and urinalysis, liver and kidney function, and coagulation function.

Table 2 Efficacy indicators

| Main efficacy indicators | Secondary efficacy measurements |
|--------------------------|---------------------------------|
| 6MWD                     | Pulmonary Hypertension WHO Classification |
| HRR1                     | Borg Dyspnea Score              |
|                          | Minnesota Living with Heart Failure Questionnaire |
|                          | NT-proBNP                       |
|                          | cTNI                            |
|                          | RVSP                            |
|                          | Uric acid                       |
|                          | Volume of pericardial effusion  |
|                          | Pulmonary artery diameter       |
|                          | Diameter of the same layer of aorta |
|                          | Arterial oxygen saturation      |
|                          | Time of clinical deterioration  |

Clinical deterioration is defined as the need to increase medication or change the therapeutic regimen for the treatment of PH, particularly inhaled, intravenous, or subcutaneous application of prostacyclin and its analogues; aggravated symptoms of right heart failure that do not respond to diuretics; atrial septostomy or death; lung transplantation; or hospitalization caused by exacerbation of PH.

Other clinical symptoms and signs, biochemical indicators, and imaging indicators are
recorded (Table 2) for comprehensive prognostic evaluation and risk assessment.

Figures

Figure 1

Flow chart for enrollment and follow-up of participants

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

SPIRIT_Fillable-checklist-5-Apr-2019.doc
sample size formula image.JPG